Bio-Rad Laboratories, Inc. (BIO)
Automate Your Wheel Strategy on BIO
With Tiblio's Option Bot, you can configure your own wheel strategy including BIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIO
- Rev/Share 90.9445
- Book/Share 239.0537
- PB 0.9493
- Debt/Equity 0.205
- CurrentRatio 0.006
- ROIC -0.3916
- MktCap 6185927760.0
- FreeCF/Share 11.8852
- PFCF 18.6276
- PE -2.8458
- Debt/Assets 0.1438
- DivYield 0
- ROE -0.3239
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BIO | Citigroup | Neutral | Buy | $350 | $400 | Oct. 1, 2024 |
| Initiation | BIO | Wells Fargo | -- | Equal Weight | -- | $340 | Aug. 28, 2024 |
News
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
Read More
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Read More
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
Read More
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President & Chief Operating Officer Roop Lakkaraju - Executive Vice President & Chief Financial Officer Norman Schwartz - Chairman of the Board, President & Chief Executive Officer Conference Call Participants Dan Leonard - UBS Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Markets Tycho Peterson - Jefferies Operator Thank you for standing by. My name is Prila [ph] and I will be your conference …
Read More
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.
Read More
About Bio-Rad Laboratories, Inc. (BIO)
- IPO Date 1980-02-27
- Website https://www.bio-rad.com
- Industry Medical - Devices
- CEO Mr. Norman D. Schwartz
- Employees 7700